Aktis Oncology, Inc. AKTS

Company Overview

Aktis Oncology, Inc. is a clinical-stage biotechnology company focused on developing targeted radiopharmaceutical therapies for solid tumors. The company operates within the oncology and precision medicine sectors, with a particular emphasis on radiopharmaceutical drug development that combines tumor-targeting agents with radioactive isotopes designed to selectively deliver therapeutic radiation to cancer cells. Aktis Oncology’s core platform is centered on identifying and developing tumor-targeting molecules capable of reaching difficult-to-treat cancers while limiting exposure to healthy tissue.

The company’s primary business focus is the development of radioconjugate therapeutics for cancers with significant unmet medical need, including solid tumors that are difficult to address through conventional chemotherapy, immunotherapy, or external beam radiation. Aktis Oncology was founded in 2021 and emerged from research and technology associated with advances in molecular imaging, radiochemistry, and targeted isotope delivery. Its strategic positioning is based on integrating targeting biology with isotope engineering and radiopharmaceutical manufacturing capabilities to support next-generation precision oncology treatments.